Arena Pharmaceuticals (ARNA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA)

ARNA 99.99

0.0%

Mar 15 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	11/25/2013 10:39:36 AM
	Read Replies (1) of 2274

Orexigen (OREX) reports interim data from their Contrave "Light" study. The key statement from the PR is as follows: "The FDA previously agreed that if the interim analysis meets the specified criteria to exclude cardiovascular risk, Contrave could be approved. The pre-specified criteria for the interim analysis is to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo. In addition to meeting the pre-specified criteria for excluding cardiovascular risk, no new safety signals were observed." ir.orexigen.com This is good news for all the obesity drug companies in my view, since many are worried about cardiovascular risk in this broad class of drugs since the days of Meridia and its inherent CV risk. OREX is up about 12% as I type this, while ARNA and VVUS are showing modest gains.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next